Advertisement

Picture Campus Berlin-Buch GmbH BBC BerlinBioCube Start-up Center 650x100px
Collaboration › Details

Bruker–Leucadia: investor conference, 202211 supply service Bruker presents at Jefferies 2022 London Healthcare Conference

 

Period Period 2022-11-15
Region Region London, Greater London
  Country United Kingdom (GB)
Organisations Partner, 1st Bruker Corporation (Nasdaq: BRKR)
  Group Bruker (Group)
  Partner, 2nd Jefferies International Ltd.
  Group Leucadia (Group)
Products Product Jefferies 2022 London Healthcare Conference
  Product 2 analytical instrument
Persons Person Herman, Gerald N. (Bruker Corp 201806– CFO before Interim CFO joined 12/16 as VP + Corp Controller before Parexel)
  Person 2 Ward, Justin (Bruker 202204 Senior Director IR + Corporate Development)
     

Bruker Corporation. (11/7/22). "Press Release: Bruker Corporation to Participate in the 2022 Jefferies London Healthcare Conference". Billerica, MA.

Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 2022 Jefferies London Healthcare Conference. Gerald Herman, Executive Vice President & Chief Financial Officer will present and participate in an analyst moderated question and answer session on behalf of the Company on Tuesday, November 15, 2022 at 12:00 PM Eastern Time.

A live audio webcast of the question and answer session will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the event and will be available for 90 days.


About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.


Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
+1 (978) 663–3660, ext. 1479
Investor.Relations@bruker.com

   
Record changed: 2022-11-08

Advertisement

Picture [iito] No Tracking 650x100px

More documents for Bruker (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Campus Berlin-Buch GmbH CBB Location of Future Innovation 650x300px




» top